LOS ANGELES–(BUSINESS WIRE)–$UNCY—The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Unicycive Therapeutics, Inc. (“Unicycive” or “the Company”) (NASDAQ: UNCY) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Unicycive announced on June 30, 2025, that the FDA “has issued a CRL [Complete Response Letter] for its New Drug Application (NDA) for OLC to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.” The Company added that “After submitting the NDA, and as a part of the application review and routine information requests, the FDA notified Unicycive that a third-party manufacturing vendor of its main contract development and manufacturing organization (CDMO) was cited for deficiencies following a cGMP inspection.” Based on this news, shares of Unicycive fell by 29.85% on the same day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Contacts
The Schall Law Firm
Brian Schall, Esq.
310-301-3335
info@schallfirm.com
www.schallfirm.com
BUENOS AIRES, Argentina, Sept. 18, 2025 /PRNewswire/ -- The Qatar Philharmonic Orchestra (QPO) launched its first…
PHNOM PENH, Cambodia, Sept. 18, 2025 /PRNewswire/ -- Under the joint guidance of the People's Bank…
Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement…
Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation…
19 September 2025 - Today, during the second day of its meeting in Milan, the…
19 September 2025 - In a world shaken by conflict and division, the International Olympic Committee…
